SGLT2 Inhibitors in Treating Patients With PCOS

Launched by SHANGHAI 10TH PEOPLE'S HOSPITAL · Jul 21, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating whether a new type of medication called SGLT2 inhibitors can help improve symptoms in women with Polycystic Ovary Syndrome (PCOS), a condition that often involves chronic inflammation and insulin resistance. The trial aims to find out if SGLT2 inhibitors can work better than the commonly used drug metformin for treating PCOS and to explore how these medications might reduce inflammation in the body.

Women between the ages of 18 and 45 who have been diagnosed with PCOS and experience insulin resistance may be eligible to participate in this study. Participants will be closely monitored to see how they respond to the treatment and to ensure their safety throughout the trial. It's important to note that women who are pregnant, breastfeeding, or have certain health conditions may not be able to join. Overall, this study hopes to provide valuable insights into new treatment options for PCOS that could lead to better health outcomes for those affected by this condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female aged 18-45
• • Meet Rotterdam criteria
• • BMI≥20kg/m2
• Exclusion Criteria:
• • Treatment with any additional medications that might impede the trial, including GLP-1 RAs, metformin, pioglitazone, contraceptives, or traditional Chinese medicine within the past 3 months
• • Pregnancy or lactation
• • Mental illness
• • Malignant tumors
• • Chronic kidney disease or severe liver dysfunction
• • Inflammatory bowel disease
• • Involvement in other research programs within the past 3 months